CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients’ needs using the latest technologies to develop and deliver innovative biotherapies that are used to treat serious and rare conditions such as coagulation disorders, primary immune deficiencies, hereditary angioedema and respiratory disease. Our R&D focus is plasma fractionation, recombinant technology, and gene and cell therapy. Visit CSLBehring.com/Vita and follow us on Twitter.com/CSLBehring.